Cutler Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-12,100
| Closed | -$22K | – | 4500 |
|
|
2023
Q2 | $22K | Buy |
12,100
+5,600
| +86% | +$530K | ﹤0.01% | 1813 |
|
|
2023
Q1 | $8K | Buy |
6,500
+3,500
| +117% | +$205K | ﹤0.01% | 2506 |
|
|
2022
Q4 | $17K | Sell |
3,000
-3,600
| -55% | -$124K | ﹤0.01% | 2361 |
|
|
2022
Q3 | $23K | Buy |
6,600
+4,800
| +267% | +$133K | ﹤0.01% | 2523 |
|
|
2022
Q2 | $6K | Sell |
1,800
-45,700
| -96% | -$1.36M | ﹤0.01% | 3646 |
|
|
2022
Q1 | $72K | Buy |
47,500
+27,900
| +142% | +$828K | ﹤0.01% | 1950 |
|
|
2021
Q4 | $121K | Buy |
19,600
+9,600
| +96% | +$743K | 0.01% | 1706 |
|
|
2021
Q3 | $8K | Buy |
10,000
+8,800
| +733% | +$1.03M | ﹤0.01% | 4165 |
|
|
2021
Q2 | $1K | Sell |
1,200
-300
| -20% | -$33.9K | ﹤0.01% | 5508 |
|
|
2021
Q1 | $13K | Buy |
+1,500
| New | +$175K | ﹤0.01% | 3604 |
|
|
2020
Q4 | – | Sell |
-3,900
| Closed | -$30K | – | 5684 |
|
|
2020
Q3 | $30K | Buy |
+3,900
| New | +$487K | ﹤0.01% | 2169 |
|
|
2019
Q4 | – | Sell |
-4,800
| Closed | -$135K | – | 4798 |
|
|
2019
Q3 | $135K | Buy |
4,800
+1,300
| +37% | +$110K | 0.01% | 907 |
|
|
2019
Q2 | $105K | Sell |
3,500
-3,000
| -46% | -$259K | 0.01% | 1077 |
|
|
2019
Q1 | $124K | Buy |
+6,500
| New | +$540K | 0.01% | 892 |
|
|
2018
Q4 | – | Sell |
-5,000
| Closed | -$6K | – | 4783 |
|
|
2018
Q3 | $6K | Buy |
+5,000
| New | +$352K | ﹤0.01% | 2983 |
|
Other funds holding RETA
Cutler Group's RETA Position: Q3 2023 in Review
Cutler Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 1,800 shares — an estimated $183K sold.
Cutler Group first reported a position in RETA in Q4 2017 and held it in 19 quarters. The position peaked at $360K in Q2 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Cutler Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Cutler Group sold 1,800 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $183K.
- Cutler Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2017 and held it in 19 quarters.
- Cutler Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $360K in Q2 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.